InvestorsHub Logo
Followers 13
Posts 1027
Boards Moderated 0
Alias Born 07/19/2013

Re: The ELTP King post# 381653

Thursday, 06/29/2023 2:26:33 PM

Thursday, June 29, 2023 2:26:33 PM

Post# of 401596
What seems to be the problem?
"On November 21, 2022, Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. (a wholly owned subsidiary of Elite Pharmaceuticals, Inc.) (collectively “Elite”) executed an agreement with Pyros Pharmaceuticals, Inc. (“Pyros”) pursuant to which the Company will sell to Pyros its rights in and to the Company’s approved abbreviated new drug applications (ANDAs) for its generic Sabril® (Vigabatrin Powder for Oral Solution, 500 mg) (“Product”). The sale has been consummated."

"Elite executed a Manufacturing and Supply agreement on November 21, 2022, with Pyros in conjunction with the sale. Under the terms of the commercial Manufacturing and Supply Agreement, Elite will be compensated at an agreed-upon price for the manufacturing and packaging of the Product for commercial sale for a term of three years."

https://www.sec.gov/ix?doc=/Archives/edgar/data/1053369/000149315222033823/form8-k.htm
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News